Commentary

We have read with great interest the study on Epidermal Growth Factor Receptor (EGFR) mutations in breast carcinoma by Ning Lv et al published in Diagnostic Pathology [1]. Since in lung cancer the choice of anti-EGFR therapy is based on the presence of EGFR activating mutations, and due to the importance to the EGFR pathway in breast cancer, it is crucial to evaluate the presence of these mutations in the different subtypes of breast cancer. The authors reported that, in their series of 139 breast cancers, two (1.4%) tumors harbored activating EGFR mutations in exon 19 and 21 of this gene. One tumor was classified as estrogen receptor (ER) (1/105, 0.8%) positive and the other was a triple negative (TN) tumor (1/10, 10%). Similarly, in a recent study on 70 TN breast cancers, which were previously described to often present an EGFR addiction, Teng et al. found 8 (11.4%) activating EGFR mutations in exon 19 and 21 [2]. Both works reported findings that were obtained using tumor samples from Asian patients. We recently analyzed a series of 229 TN tumor samples from European patients with primary breast cancer and found that none had activating EGFR mutations [3]. In previous reports concerning smaller series of Caucasians patients, no EGFR activating mutation was found whatever the subtype of breast cancer studied [4–6]. Similarly, in a cohort of 58 Japanese patients, Toyama et al failed to find exon 19 and 21 EGFR mutations [7]. These results underline geographic differences in the presence of EGFR activating mutations as it was already described for non-small cell lung cancer [8]. This mutational event, which appears to be mostly limited to Chinese patients with TN breast cancer, could be related to ethnic or environmental factors. However, the question of the origin of the geographical variations in the occurrence of EGFR mutations in lung and breast cancers is unresolved.

Interestingly, a case of breast metastasis from a primary lung cancer that was confirmed by the detection of the same EGFR mutation has been recently reported [9]. This observation confirms that the presence of this mutation is not an obstacle to metastasization/tumor cell growth in the breast microenvironment. Inversely, we should not forget that some breast cancer characteristics, like ER expression and HER2 over-expression, have been also described in lung cancers [10, 11]. Lung and breast cancer subtypes seem to share some biomarkers and thus could respond to the same therapies.

At the time of personalized medicine in oncology, more than ever, molecular patterns break the limits of classifying tumors according to their localization. Mutation profiles have to be analyzed in sub-groups of specific populations. This is a new and promising challenge for the design of clinical trials involving targeted therapies.